MHC-HM415T-100μg / 询价
MHC-HM415T-500μg / 询价
MHC-HM415T-500μgx2 / 询价
- 客服电话
- 技术支持
Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Tetramer Protein
Recombinant Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus,tetramer is assembled by biotinylated monomer and streptavidin. It contains Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and HMTEVVRHC peptide.[Accession | A0A140T913(HLA-A*02:01)&P61769(B2M)&HMTEVVRHC]
The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.
Less than 1EU per μg by the LAL method.
> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Tetramer on Tris-Bis PAGE under Non reducing (N) condition. The purity is greater than 95%.
The purity of Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Tetramer is greater than 95% as determined by SEC-HPLC.
Immobilized Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Tetramer, His Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Antibody , hFc Tag with the EC50 of 9.7ng/ml determined by ELISA.
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein.p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth.
MHC; HLA-A; P53; TP53; Antigen NY-CO-13; BCC7; FLJ92943; LFS1; TRP53
(1) Kanapathipillai M. Treating p53 Mutant Aggregation-Associated Cancer. Cancers (Basel). 2018 May 23;10(6):154. doi: 10.3390/cancers10060154. PMID: 29789497; PMCID: PMC6025594.
